Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier:
NCT01272050
First received: January 6, 2011
Last updated: April 29, 2014
Last verified: April 2014

January 6, 2011
April 29, 2014
January 2011
January 2015   (final data collection date for primary outcome measure)
Freedom from biochemical progression [ Time Frame: from the day of trial randomization to the day of either first recorded biochemical progression, or death due to clinical progression. ] [ Designated as safety issue: No ]
Freedom from biochemical progression [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01272050 on ClinicalTrials.gov Archive Site
  • Clinical progression-free survival [ Time Frame: from the day of randomization to the day of the first record of either local or regional recurrence, distant recurrence, start of hormonal treatment, or death due to any cause ] [ Designated as safety issue: No ]
  • Time to hormonal treatment [ Time Frame: time from trial randomization to start of hormonal treatment ] [ Designated as safety issue: No ]
  • Prostate cancer-specific survival [ Time Frame: time from trial randomization to the date of death due to prostate cancer ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: time from trial randomization to the date of death from any cause ] [ Designated as safety issue: No ]
  • Acute and late gastrointestinal and genitourinary toxicity according to CTCAE v 4.0 [ Time Frame: occurring during treatment and up to 3 months after completion of treatment. Late toxicity is defined as occurring later than 3 months after end of treatment. ] [ Designated as safety issue: Yes ]
  • Quality of life [ Time Frame: n.a. ] [ Designated as safety issue: No ]
  • Clinical progression-free survival [ Designated as safety issue: No ]
  • Time to hormonal treatment [ Designated as safety issue: No ]
  • Prostate cancer-specific survival [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
  • Acute and late gastrointestinal and genitourinary toxicity according to CTCAE v 4.0 [ Designated as safety issue: Yes ]
  • Quality of life [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery
Dose Intensified Salvage Radiotherapy in Biochemically Relapsed Prostate Cancer Without Macroscopic Disease. A Randomized Phase III Trial.

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with relapsed prostate cancer.

PURPOSE: This randomized phase III trial is studying the side effects of radiation therapy and comparing two radiation therapy regimens in treating patients with relapsed prostate cancer after surgery.

OBJECTIVES:

  • To determine the tumor control in patients with biochemically relapsed prostate cancer without macroscopic disease treated with dose-intensive salvage radiotherapy.
  • To determine the toxicity in these patients.
  • To determine the quality of life of these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to Gleason score (≥ 8 vs 7 vs ≤ 6), pathological tumor classification (pT3b vs others), lymphadenectomy performed (yes [pN0] vs no [cN0]), persistent PSA after prostatectomy (detectable [≥ 0.1 ng/mL] vs undetectable [< 0.1 ng/mL]), PSA at randomization (> 0.5 ng/mL vs ≤ 0.5 ng/mL), participating center, and radiotherapy technique (3-dimensional conformal radiation therapy [3D-CRT] vs intensity-modulated radiation therapy [IMRT]/rotational techniques). Patient are randomized to 1 of 2 treatment arms.

  • Arm A: Beginning at least 12 weeks after surgery, patients undergo radiotherapy* once a day, 5 days a week, for 6.4 weeks for a total dose of 64 Gy (in 32 fractions of 2 Gy over 6.4 weeks).
  • Arm B: Patients undergo radiotherapy* once a day, 5 days a week, for 7 weeks for a total dose of 70 Gy (in 35 fractions of 2 Gy over 7 weeks).

NOTE: *3-dimensional conformal radiation therapy, rotational techniques such as Tomotherapy®, Rapidarc®, or intensity-modulated arc technique and volumetric-modulated arc therapy are all eligible.

Patients complete quality-of-life questionnaires at baseline and at 3, 12, 24, 36, 48, and 60 months after completing study therapy.

After completion of study treatment, patients are followed every 6 months for 3 years and then every 12 months for up to 10 years.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
Radiation: radiation therapy

RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.

Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration.

  • Active Comparator: Arm A: 64 Gy
    Arm A: 64 Gy (32 x 2 Gy) without hormonal treatment
    Intervention: Radiation: radiation therapy
  • Active Comparator: Arm B: 70 Gy
    Arm B: 70 Gy (35 x 2 Gy) without hormonal treatment
    Intervention: Radiation: radiation therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
350
December 2025
January 2015   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of adenocarcinoma of the prostate

    • Lymph node negative disease

      • Stage pT2a-3b; R0-1; pN0 or cN0
  • Undergone a radical prostatectomy ≥ 12 weeks prior to randomization
  • PSA progression after prostatectomy defined as two consecutive rises with the second rising value > 0.1 ng/mL OR three consecutive rises (the first value must be measured 4 weeks after radical prostatectomy)
  • PSA ≤ 2 ng/mL at randomization

    • No persistent PSA > 0.4 ng/mL, 4-20 weeks after radical prostatectomy
  • No palpable prostatic fossa mass suggestive of recurrence, unless an ultrasound-guided biopsy is non-malignant
  • No pre-salvage radiotherapy pelvic lymph node enlargement > 1 cm in short axis diameter of the abdomen and pelvis (cN1) (unless the enlarged lymph node is sampled and negative)
  • No evidence of macroscopic local recurrence or metastatic disease on pre-salvage radiotherapy MRI (with IV contrast) or multislice computed tomography (with IV and oral contrast) of the abdomen and pelvis assessed within 16 weeks prior to randomization
  • No presence or history of bone metastases (bone scan must be performed in case of clinical suspicion [e.g., bone pain])
  • Gleason score must be available

PATIENT CHARACTERISTICS:

  • WHO performance status 0-1
  • Fertile patients must use effective contraception during and for 6 months after completion of study therapy
  • Compliant and geographically proximal to allow for proper staging and follow-up
  • No prior invasive malignancy, except non-melanomatous skin cancer or other malignancies with a documented disease-free survival of ≥ 5 years
  • No bilateral hip prosthesis
  • No severe or active co-morbidity likely to impact on the advisability of dose-intensive salvage radiotherapy, including any of the following:

    • History of inflammatory bowel disease
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of randomization
    • Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
    • Transmural myocardial infarction within the past 6 months
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of randomization
  • No psychiatric disorder precluding understanding of information on trial-related topics, giving informed consent, or filling out quality-of-life questionnaires

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior pelvic radiotherapy
  • No hormonal treatment or bilateral orchiectomy prior to or following prostatectomy
  • At least 4 weeks since prior and no concurrent use of products known to affect PSA levels (e.g., PC Calm, PC Plus, PC SPES, finasteride, or fluconazole)
  • At least 30 days since prior treatment in another clinical trial
  • No other concurrent anticancer treatments, including luteinizing hormone-releasing hormone (LHRH) analogues, antiandrogens, orchiectomy, or chemotherapy
  • No other concurrent investigational or experimental treatments or drugs

INCLUSION CRITERIA

  • Patient must give written informed consent before randomization.
  • Lymph node negative adenocarcinoma of the prostate treated with radical prostatectomy at least 12 weeks before randomization. Tumor stage pT2a-3b, R0-1, pN0 or cN0 according to the UICC TNM 2009 (see Appendix 1), Gleason score available.
  • PSA progression after prostatectomy defined as two consecutive rises with the final PSA > 0.1 ng/mL or three consecutive rises. The first value must be measured earliest 4 weeks after radical prostatectomy.
  • PSA at randomization ≤ 2 ng/mL.
  • WHO performance status 0-1 at randomization.
  • Age at randomization between 18 and 75 years.
  • Baseline QoL questionnaire (QLQ) has been completed.
  • Patient agrees not to father a child during salvage RT and during 6 months thereafter.
  • Patient compliance and geographic proximity allow proper staging and follow-up.
  • The responsible pathologist has agreed to provide sample material for central pathological review (see Section 16) and tissue banking (only if patient gave informed consent) within the specified timelines.

EXCLUSION CRITERIA

  • Persistent PSA 4-20 weeks after radical prostatectomy > 0.4 ng/mL
  • Palpable prostatic fossa mass suggestive of recurrence, unless an ultrasound guided biopsy is non-malignant.
  • Pre-salvage RT pelvic lymph node enlargement > 1 cm in short axis diameter of the abdomen and pelvis (cN1), unless the enlarged lymph node is sampled and negative, and/or evidence of macroscopic local recurrence or metastatic disease on pre-salvage RT MRI (magnetic resonance imaging; with i.v. contrast) or multislice computed tomography (CT; with i.v. and oral contrast) of the abdomen and pelvis assessed within 16 weeks prior to randomization.
  • Presence or history of bone metastases. Bone scan must be performed in case of clinical suspicion (e.g. bone pain).
  • Prior invasive malignancy, except non-melanomatous skin cancer or other malignancies with a documented disease-free survival for a minimum of 5 years.
  • Hormonal treatment or bilateral orchiectomy prior to or following prostatectomy.
  • Bilateral hip prosthesis.
  • Prior pelvic radiotherapy.
  • The use of products known to affect PSA levels within 4 weeks prior to start of trial treatment (e.g. PC Calm, PC Plus, PC SPES, finasteride, fluconazole).
  • Severe or active co-morbidity likely to impact on the advisability of dose intensified salvage RT.
  • Psychiatric disorder precluding understanding of information on trial related topics, giving informed consent or filling out QoL questionnaires.
  • Concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to trial entry.
Male
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Germany,   Switzerland
 
NCT01272050
SAKK 09/10, SWS-SAKK-09/10, EU-21088, CDR0000691926
No
Swiss Group for Clinical Cancer Research
Swiss Group for Clinical Cancer Research
Not Provided
Study Chair: Pirus Ghadjar, MD Charité Berlin
Study Chair: Daniel M. Aebersold, Prof. Bern University Hospital
Study Chair: George N. Thalmann, Prof. Bern University Hospital
Study Chair: Daniel Zwahlen, PD Dr. Kantonsspital Graubünden
Swiss Group for Clinical Cancer Research
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP